Isofol Medical

Isofol is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate, Modufolin®, is predicted to improve the outlook for cancer patients undergoing chemotherapy treatment with a range of antimetabolites. Isofol’s ongoing clinical trials are focusing on colorectal cancer and osteosarcoma. Isofol collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates.

Full Story >

stor orange

Modufolin® development

Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma.
 
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.

Read more about Modufolin

Stay informed

Click the link below to stay informed about our progress.

Clinical trials

To find out the latest news about our ongoing clinical phase II trial please go to:

Development pipeline

Click the link below to find out more about our development pipeline:

News & Press information

Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®
3/14/2016: Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment to support the clinical program with Modufolin®, Isofol’s lead drug candidate. Modufolin® is a novel folate-based compound being developed to increase the efficacy and reduce the side effects of chemotherapeutic agents used in the treatment of solid tumors.
Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment
12/10/2015: Isofol Medical AB today announced that the first dose cohort with Modufolin® as rescue therapy, after treatment with two cycles of HDMTX, fulfilled the study objectives in the ongoing Phase I/II open-label, multicenter clinical trial, ISO-MTX-003. In total four patients with osteosarcoma have successfully completed their treatment with Modufolin® at 15 mg/m2. Isofol is now initiating a second dose cohort where 3-6 patients will be treated with 7.5 mg/m2 of Modufolin®. This is a safety/efficacy study and is intended to identify the dose with most favorable safety that mitigates HDMTX induced toxicity.
Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden
Phone: +46 (0) 707 64 65 00 E-mail: info@isofolmedical.com